Boston, MA -- (SBWIRE) -- 04/10/2014 -- Pharmaceutical firms in India are reporting improved performance for the quarter ended December 2013. This is an early indication of a recovery in the Indian pharmaceutical industry, following the implementation of the Drug Price Control Order in May 2013. While we forecast strong growth for the sector in 2014, persisting issues such as the halting of clinical trials, low healthcare expenditure and company-specific manufacturing quality control problems will continue to pose downside risks to our outlook.
Headline Expenditure Projections
Pharmaceuticals: INR904.0bn (US$15.4bn) in 2013 to INR995.8bn (US$17.2bn) in 2014; +10.2% in local currency terms and +11.2% in US dollar terms.
Healthcare: INR4,214.5bn (US$72.0bn) in 2013 to INR4,646.2bn (US$80.1bn) in 2014; +10.2% in local currency terms and 11.3% in US dollar terms.
View Full Report Details and Table of Contents
India's Pharmaceutical Risk/Reward Rating (RRR) score for Q214 is 51.8 out of the maximum 100, in our newly improved RRR system. The country scored above average for some indicators and sub-indicators including overall market expenditure, sector value growth, population growth. Nevertheless, it scored below regional average for most indicators under industry and country risks. Consequently with the moderate score, India is ranked tenth, behind New Zealand, out of the 19 key markets in Asia Pacific.
Key Trends And Developments
- From March 1 2014 a total of 46 drugs will be classified in India under a new category called 'Schedule H1'. Medicines listed on Schedule H1 can only be dispensed by a pharmacist with a prescription given by registered medical practitioners. Retailers are also expected to maintain separate records of sales of these medicines for at least two years. Drugs that are listed on Schedule H1 include third and fourth generation antibiotics, anti-tuberculosis medicines and other drugs in a bid to address the issue of drug resistance in the country, resulting from the improper prescription and consumption of antibiotics.
- In February 2014, just days after Mylan announced the launch of its biosimilar trastuzumab in India, which was developed in partnership with Indian firm Biocon, Roche was granted an injunction in the High Court of Delhi against the biosimilar. Roche markets trastuzumab under the brand name Herceptin, and also markets it in India under the brand names Herclon and Biceltis. It is indicated for the treatment of HER2+ metastatic breast cancer.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Sweden Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Bangladesh Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q2 2014
- Thailand Pharmaceuticals & Healthcare Report Q2 2014
- Kazakhstan Pharmaceuticals & Healthcare Report Q2 2014
- Lebanon Pharmaceuticals & Healthcare Report Q2 2014
- Japan Pharmaceuticals & Healthcare Report Q2 2014